The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | The differences in outcomes and treatment in CLL patients with mutated and unmutated IGHV
Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid,
Spain, discusses the differences in patient outcomes observed in patients with mutated immunoglobulin heavy chain variable regions (IGHV) and unmutated IGHV in chronic lymphocytic leukemia, (CLL) as well as the disparities in patient outcomes in frontline targeted therapies within the two groups. Dr Cordoba comments on the necessity to use IGHV as a
biomarker before a decision on treatment strategy is made. This interview took place at the 20thInternational Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
